argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus
Go back to argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus| (NASDAQ: ARGX) | Delayed: 1007.07 -26.08 (2.52%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1033.15 | 52 Week High | $ | |||
| Open | $1005.68 | 52 Week Low | $ | |||
| Day High | $1015.79 | P/E | N/A | |||
| Day Low | $995.00 | EPS | $ | |||
| Volume | 313,873 | |||||
| (NASDAQ: ARGX) | Delayed: 1007.07 -26.08 (2.52%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1033.15 | 52 Week High | $ | |||
| Open | $1005.68 | 52 Week Low | $ | |||
| Day High | $1015.79 | P/E | N/A | |||
| Day Low | $995.00 | EPS | $ | |||
| Volume | 313,873 | |||||

